Health news and discussion on TalkFuse.
FDA to require vision loss warning on popular GLP-1 medicines
The FDA will require makers of popular GLP-1 medicines, including Ozempic, Wegovy, Zepbound and Mounjaro, to add a warning about a possible increased risk of NAION, a rare condition that can cause sudden, often permanent vision loss. The warning is intended to make patients aware, although the evidence does not establish that the medicines cause the condition.
NAION results from restricted blood flow to the optic nerve and affects an estimated two to 10 people in every 100,000 in the general population. Studies of a possible link have produced mixed results: a 2024 study reported higher rates among GLP-1 users, but had limitations, while later research has found both associations and no clear link. Diabetes and other conditions common among GLP-1 users are also NAION risk factors, making the relationship harder to assess.
In short
- FDA is adding a warning about possible NAION risk to GLP-1 drug labels.
- NAION is rare and can cause sudden, permanent vision loss.
- Research on whether GLP-1 medicines raise the risk remains mixed.
Read the full article at the source →
Originally published by Ars Technica as “FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss”.